Synopsis
Many pharmacy practitioners have refocused their attention upon in-house sterile compounding as a critical segment of their medication management operations due to the challenges posed by multiple drug shortages, a growing demand for operational efficiencies, cost avoidance strategies, and an increased emphasis on risk mitigation strategies in the wake of the outsourced compounding tragedies that struck late last year. As part of this renewed focus, organizations are considering a capital investment in upgrading, expanding, or modernizing existing compounding capabilities or the construction of entirely new cleanrooms.
